Centessa Pharmaceuticals
CNTA----
Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
Centessa Pharmaceuticals Analyst Rating
View moreForecast & Rating
Jun 10, 2026Price forecast
$44.179.05%
Forecast & RatingBuy
12analysts
- Strong buy25.00%
- Buy8.33%
- Hold66.67%
- Sell0.00%
- Strong sell0.00%
News
- Wallstreetcn ·
From Weight-Loss Drugs to Sleep Disorders! Lilly Plans to Acquire Centessa for Up to $7.8 Billion, Entering Narcolepsy and Wakefulness Disorder Treatment Fields
- Wallstreetcn ·
U.S. Stocks Open Higher: Nasdaq Up 1.3%, Dow Up 1.1%
- Wallstreetcn ·
Lilly to acquire Centessa Pharmaceuticals for $38 per share plus CVRs (Contingent Value Rights). (Bloomberg)
